InvestorsHub Logo
Followers 5
Posts 483
Boards Moderated 0
Alias Born 05/01/2019

Re: JimmyRich post# 13716

Wednesday, 06/12/2024 2:15:51 PM

Wednesday, June 12, 2024 2:15:51 PM

Post# of 13869
The FDA would have followed up with UHP on the Hemostyp application within 45 days of submission.

Since there are no rules or expectations from the FDA or SEC implying that they can’t share the information, UHP is choosing to not share it.

When they had positive application status in 2021 they shared the information immediately:

May 5,2021

“following the resubmission of its application for Pre-market Approval for HemoStyp gauze on April 6th, the FDA has now accepted for review and commenced its Substantive Review of the application.”

It’s anyone’s guess from here, but I think my point is clear.